Updates are available Correction dated 2023-04-28
Click to view Correction: https://doi.org/10.1007/s13340-023-00632-2
-
Authors
Teshigawara, Sanae
Tone, Atsuhito http://orcid.org/0000-0003-4335-1516
Katayama, Akihiro
Imai, Yusuke
Tahara, Toshihisa
Senoo, Mayumi
Watanabe, Satoko
Kaneto, Mitsuhiro
Shimomura, Yasuyuki
Yagi, Chiaki
Kajioka, Hiroki
Kojima, Toru
Niguma, Takefumi
Nakatou, Tatsuaki
-
Funding
Funding for this research was provided by:
Sanofi K.K.
Eli Lilly Japan
Abbott Japan
Novo Nordisk Pharma
Dainippon Sumitomo Pharma
- License Information
-
More Information
Article History
Received: 12 October 2022
Accepted: 7 March 2023
First Online: 1 April 2023
Change Date: 28 April 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s13340-023-00632-2
Declarations
:
: Author Atsuhito T. received lecture fees from Sanofi, Eli Lilly, and Abbott. Author Tatsuaki N. received lecture fees from Eli Lilly Japan, Novo Nordisk Pharma, and Sumitomo Dainippon Pharma. Other authors declare that they have no conflict of interest associated with this research.
: All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. This study was approved by the ethics committee of Okayama Saiseikai General Hospital (approval no. 190303; approval date February 25<sup>th</sup>, 2019). We did not receive informed consent, but we provided the participants with the opportunity to refuse by publishing the Opt Out document.
